

```

<!--StartFragment-->RESULT 4
ABP69553
ID   ABP69553 standard; protein; 836 AA.
XX
AC   ABP69553;
XX
DT   15-JUN-2007 (revised)
DT   20-JAN-2003 (first entry)
XX
DE   Human polypeptide SEQ ID NO 1600.
XX
KW   Human; genome mapping; gene therapy; food supplement; virus; fungus;
KW   cell-proliferative disorder; neurodegenerative disease; bacterial;
KW   Parkinson's disease; Alzheimer's disease; autoimmune disease;
KW   multiple sclerosis; diabetes; genetic disorder; wound; burn; infection;
KW   arthritis; cytostatic; immunomodulator; nootropic; neuroprotective;
KW   antiparkinsonian; antidiabetic; immunosuppressive; dermatological;
KW   haemostatic; vulnerary; fungicide; antibacterial; virucide; protozoacide;
KW   antiarthritic; BOND_PC; CUB domain containing protein 1, isoform CRA_a;
KW   CUB domain containing protein 1, isoform CRA_a [Homo sapiens];
KW   CUB domain containing protein 1;
KW   CUB domain containing protein 1 [Homo sapiens]; G05194; G06942; G07517;
KW   G08307; G016020; G016021.
XX
OS   Homo sapiens.
XX
PN   WO200270539-A2.
XX
PD   12-SEP-2002.
XX
PF   05-MAR-2002; 2002WO-US005095.
XX
PR   05-MAR-2001; 2001US-00799451.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT, Zhou P, Goodrich RW, Asundi V, Zhang J, Zhao QA, Ren F;
PI   Xue AJ, Yang Y, Ma Y, Yamazaki V, Chen R, Wang Z, Ghosh M;
PI   Wehrman T, Wang J, Wang D, Drmanac RT;
XX
DR   WPI; 2002-759812/82.
DR   N-PSDB; ABZ11770.
DR   PC:NCBI; g14328879.
DR   PC:SWISSPROT; Q9H5V8.
XX
PT   New polynucleotides comprising sequences assembled from expressed
PT   sequence tags (ESTs), useful for treating cell-proliferative,
PT   neurodegenerative, autoimmune, genetic, myeloid or lymphoid, or platelet
PT   or coagulation disorders.
XX
PS   Claim 9; SEQ ID NO 1600; 1012pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated polynucleotide (I) comprising a
CC   nucleotide sequence selected from any of 948 sequences (ABZ11119-
CC   ABZ12066) or their mature protein coding portion, active domain coding
CC   protein or complementary sequences. The polynucleotides are useful for
CC   identifying expressed genes or for physical mapping of human genome. The
CC   encoded polypeptides (ABP68902-ABP69849) are useful as molecular weight
CC   markers, as a food supplement, for generating antibodies, in medical
CC   imaging, screening and diagnostic assays and for treating cell-
CC   proliferative disorders (cancer), neurodegenerative diseases (Parkinson's

```

CC or Alzheimer's disease), autoimmune diseases (multiple sclerosis,
 CC diabetes, lupus) genetic disorders, myeloid or lymphoid disorders,
 CC platelet or coagulation disorders, wound, burns, incision, ulcers, liver
 CC or lung fibrosis, infections (bacterial, viral, fungal, parasitic),
 CC arthritis, etc. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 836 AA;

Query Match 99.8%; Score 4387; DB 5; Length 836;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 835; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	1	MAGLNCGVSIALLGVLLGGAARLPRGAFAFEIALPRESNITVLIKLGTPTLLAKPCYIVI	60
Db	1	MAGLNCGVSIALLGVLLGGAARLPRGAFAFEIALPRESNITVLIKLGTPTLLAKPCYIVI	60
Qy	61	SKRHITMSIKSGERIVFTFSCQSPENHFVIEIQKNIDMSGPCPFGEVQLQPSSTLLPT	120
Db	61	SKRHITMSIKSGERIVFTFSCQSPENHFVIEIQKNIDMSGPCPFGEVQLQPSSTLLPT	120
Qy	121	LNRTFIWVDKAHKSIGLELQFSIPRLRQIGPGESCPOGVTHSISGRIDATVVRIGTFCSN	180
Db	121	LNRTFIWVDKAHKSIGLELQFSIPRLRQIGPGESCPOGVTHSISGRIDATVVRIGTFCSN	180
Qy	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Db	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Qy	241	PEGFPPEDELMTWQFVVPAAHLRASVSFLNFNLSNCERKEERVEYIIPGSTTNPVEVFKLEDK	300
Db	241	PEGFPPEDELMTWQFVVPAAHLRASVSFLNFNLSNCERKEERVEYIIPGSTTNPVEVFKLEDK	300
Qy	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Db	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Qy	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLMMNVEKTIISCTDH	420
Db	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLMMNVEKTIISCTDH	420
Qy	421	RYCQRKSYSLQVPSDILHLPVELHDFSWMKLLVPKDRLSLVLPQAQLQOHTHEKPCNTSF	480
Db	421	RYCQRKSYSLQVPSDILHLPVELHDFSWMKLLVPKDRLSLVLPQAQLQOHTHEKPCNTSF	480
Qy	481	SYLVASAIQSDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSQQEASRQGLTVSFIPY	540
Db	481	SYLVASAIQSDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSQQEASRQGLTVSFIPY	540
Qy	541	FKEEGVFTVTPDTSKSVYLRTPNWDRLPSLTSVSNISVPRDQVACLTFKERSGVVCQ	600
Db	541	FKEEGVFTVTPDTSKSVYLRTPNWDRLPSLTSVSNISVPRDQVACLTFKERSGVVCQ	600
Qy	601	TGRAFMIIQEQRTRAEEIFSLDEDVLPKPSFHHSFVWNISNCSPTSGKQLDLLFSVTLT	660
Db	601	TGRAFMIIQEQRTRAEEIFSLDEDVLPKPSFHHSFVWNISNCSPTSGKQLDLLFSVTLT	660

```

Qy      661  PRTVDLTVILIAAVGGVLLLSALGLIICCVKKKKKKTNKGPAVGIYNDNINTEMPRQPK 720
      ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      661  PRTVDLTVILIAAVGGVLLLSALGLIICCVKKKKKKTNKGPAVGIYNGNINTEMPRQPK 720

Qy      721  KFKQGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVDTYRPFQGTMGVCPPSPPTIC 780
      ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      721  KFKQGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVDTYRPFQGTMGVCPPSPPTIC 780

Qy      781  SRAPTAKLATEEPPPRSPPESESEPYTFSHPNNGDVSSKDDIPLLNTQEPMEPAE 836
      ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      781  SRAPTAKLATEEPPPRSPPESESEPYTFSHPNNGDVSSKDDIPLLNTQEPMEPAE 836

```

<!--EndFragment-->